ANTICOAGULANTS Flashcards
antiCLOTTING drugs includes the following groups…
- antiCOAGULANT drugs → effective in treatment of venous & arterial thrombosis
- thrombolytics → effective in treatment of venous & arterial thrombosis
- antiPLATELET drugs → used primarily for treatment of arterial disease
ANTICOAGULANTS:
- heparin
- LMW fraction heparins
- fondaparinux
- vit. K antagonists
- direct THROMBIN inhibitors
- factor X inhibitors
heparin → mechanism of action:
bind to antithrombin III (ATIII) → inactivates coagulation factors (esp. factor X = stuart factor) & thrombin
heparin → pharmacokinetics:
- IV administration → ass. with ACUTE states
- SC administration → more long-term treatment
- monitored with aPTT test
- safe in PREGNANCY
heparin → indications:
acute thromboembolic disorders:
- peripheral and pulmonary embolism
- venous thrombosis
- coagulopathies (DIC)
prophylaxis:
- arterial and heart surgery
- blood transfusion
- renal dialysis
- prevent embolization in atrial fibrillation
- prevent DVT & pulmonary embolism
- heart attacks
- alright to use during PREGNANCY (compared to warfarin which cross the placenta → may cause bleeding to the fetus)
heparin → CONTRAindications:
- hypersensitivity
- bleeding disorders
- alcoholism
- recent surgery of brain, eye, spinal cord
heparin → side effects:
- most common = bleeding
- two types of heparin-induced thrombocytopenias (HIT)
- prolonged use → ass. with osteoporosis
- hyperkalemia → suppression of aldosterone secretion
- chills, fever
- anaphylactic shock
LMW heparins:
- enoxaparin
- dalteparin
- tinzaparin
- bemiparin
- certoparin
- nadroparin
- parnaparin
- reviparin
LMW heparins → mechanism of action:
inactivates active factor X (Xa/stuart factor) → unlike heparin the LMW heparins cannot inactivate thrombin
LMW heparins → pharmacokinetics:
- SC administration → 1-2/day
- monitoring in → obese, renal impairment & PREGNANCY
LMW heparins → indications:
- PREVENTION of thromboembolism ass. with abdominal surgery, knee or hip replacement
- ischemic complications of unstable angina, acute coronary syndrome, angioplasty
fondaparinux → mechanism of action:
- even more selective factor Xa inhibitor
- binds antithrombin → acc. inhibition of factor Xa
- in contrast to heparin → fondaparinux does NOT inhibit thrombin
fondaparinux → pharmacokinetics:
given SC once daily
fondaparinux → indications:
- treatment & prophylaxis of DVT
2. prevention of thromboembolism in hip fracture, hip or knee replacement surgery
fondaparinux → side effects:
- bleeding (no reversal treatment)
2. HIT less likely than with heparin